Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 17, 2008

Invitrogen Set to Provide Comprehensive Noncoding RNA Portfolio

  • Invitrogen and IMBcom signed an exclusive license agreement to commercialize new noncoding RNA. The content was predicted by an algorithm and experimentally validated by the University of Queensland, Australia.

    With the expanded content, Invitrogen says that they will be the first company to provide a comprehensive noncoding RNA product portfolio to the research community. Invitrogen will commercialize these sequences over the next few years, allowing the firm to expand its NCode™ miRNA microarray product line into the field of noncoding RNA profiling.

    By combining the coding and noncoding sequences on the same microarray, researchers can obtain more information from a single sample to better reveal the relationship between noncoding RNA expression and mRNA expression. This is particularly important for scientists studying cancer and stem cells, for such RNAs have been implicated in both of these areas.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »